Carelabs Co Ltd is an Ireland based company engages in the provision of healthcare information technology services. The company provides clinic information, clinic customer management software, and digital marketing solutions. Its healthcare media platform includes GoodDak, a mobile medical information service; and Barbietk, a healthcare service that shares domestic cosmetic, skin care, and diet reviews.
2012
n/a
Last FY Revenue $60.5M
Last FY EBITDA -$9.0M
$3.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Carelabs achieved revenue of $60.5M and an EBITDA of -$9.0M.
Carelabs expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Carelabs valuation multiples based on analyst estimatesNTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|
Revenue | XXX | $60.5M | XXX | XXX | XXX |
Gross Profit | XXX | $59.7M | XXX | XXX | XXX |
Gross Margin | XXX | 99% | XXX | XXX | XXX |
EBITDA | XXX | -$9.0M | XXX | XXX | XXX |
EBITDA Margin | XXX | -15% | XXX | XXX | XXX |
EBIT | XXX | -$3.2M | XXX | XXX | XXX |
EBIT Margin | XXX | -5% | XXX | XXX | XXX |
Net Profit | XXX | -$14.7M | XXX | XXX | XXX |
Net Margin | XXX | -24% | XXX | XXX | XXX |
Net Debt | XXX | $9.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Carelabs's stock price is KRW 3060 (or $2).
Carelabs has current market cap of KRW 59.4B (or $43.2M), and EV of KRW 5.3B (or $3.8M).
See Carelabs trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$3.8M | $43.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Carelabs has market cap of $43.2M and EV of $3.8M.
Carelabs's trades at 0.1x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Carelabs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Carelabs's P/E ratio is not available.
See valuation multiples for Carelabs and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $43.2M | XXX | $43.2M | XXX | XXX | XXX |
EV (current) | $3.8M | XXX | $3.8M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | 0.1x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | -0.4x | XXX | XXX | XXX |
EV/EBIT | n/a | XXX | -1.2x | XXX | XXX | XXX |
EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | -2.9x | XXX | XXX | XXX |
EV/FCF | n/a | XXX | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCarelabs's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Carelabs's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Carelabs's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Carelabs and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | -15% | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 104% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Carelabs acquired XXX companies to date.
Last acquisition by Carelabs was XXXXXXXX, XXXXX XXXXX XXXXXX . Carelabs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was Carelabs founded? | Carelabs was founded in 2012. |
Where is Carelabs headquartered? | Carelabs is headquartered in South Korea. |
Is Carelabs publicy listed? | Yes, Carelabs is a public company listed on KRX. |
What is the stock symbol of Carelabs? | Carelabs trades under 263700 ticker. |
When did Carelabs go public? | Carelabs went public in 2018. |
Who are competitors of Carelabs? | Similar companies to Carelabs include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
What is the current market cap of Carelabs? | Carelabs's current market cap is $43.2M |
Is Carelabs profitable? | Yes, Carelabs is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.